
Sign up to save your podcasts
Or


Large cap biotech analyst Matthew Harrison talks with Chief Cross-Asset Strategist Andrew Sheets to discuss the latest timeline for a coronavirus vaccine, hurdles to success and possible market reactions.
By Morgan Stanley4.8
12461,246 ratings
Large cap biotech analyst Matthew Harrison talks with Chief Cross-Asset Strategist Andrew Sheets to discuss the latest timeline for a coronavirus vaccine, hurdles to success and possible market reactions.

1,713 Listeners

977 Listeners

406 Listeners

1,173 Listeners

2,175 Listeners

199 Listeners

686 Listeners

1,044 Listeners

191 Listeners

71 Listeners

80 Listeners

1,573 Listeners

435 Listeners

212 Listeners

118 Listeners

80 Listeners

0 Listeners